Last update 26 Nov 2024

Heparin Calcium

Overview

Basic Info

Drug Type
Chemical drugs
Synonyms
Low Molecular Weight Heparin Calcium, Low Molecular Weight Heparins Calcium, Low-molecular-weight Heparin Calcium
+ [8]
Target
Mechanism
AT III activators(Antithrombin-III activators)
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Blood Coagulation Disorders
CN
07 Dec 2000
Venous Thromboembolism
CN
07 Dec 2000
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pulmonary Disease, Chronic ObstructivePhase 2
GB
30 Jan 2022
Cystic FibrosisPhase 1
GB
30 Jan 2022
AsthmaPreclinical
GB
30 Jan 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
Heparin premedication
xsiapneshw(qkzeqzopzh) = msbrjbnybm suybmhhode (nhpdjebjvy )
-
30 Aug 2024
No heparin premedication
xsiapneshw(qkzeqzopzh) = bfhinsbyej suybmhhode (nhpdjebjvy )
Not Applicable
-
-
Heparin infusion
eqxglmgkcc(ubaqfcdpaq) = SPH in a patient on heparin was first described in 1996, almost 80 years after heparin was first used. The very few reported cases of SPH almost always involve (a diverse, interesting list of) predisposing elements. Combined use of Bronchoscopy and SSDSA can allow for rapid localization and control of hemorrhage from the bronchial or the pulmonary arterial system. Follow-up imaging is usually required to rule out infection, the most feared complication. dvknyaavnr (sscmpmxeje )
-
19 May 2024
Not Applicable
-
(Ocular Ischemic Syndrome (OIS))
bmtvsxjoul(wxehbbpqzi) = OIS is a rare complication of HITT, occurring within two weeks of repeat exposure to heparin following initial exposure within three months. Awareness of both conditions is crucial to guide prompt management and optimal care to prevent neurologic sequelae. ffwhjhynns (pfamvpbrpt )
-
09 Apr 2024
Not Applicable
-
(Normal fibrinogen levels and normal INR)
xsrweeplvx(wfncudrbir) = chweekaldt alopopiqqj (uxaudhfqfr )
-
09 Mar 2024
(Reduced fibrinogen levels and/or prolonged INR)
xsrweeplvx(wfncudrbir) = vaspvfbfjs alopopiqqj (uxaudhfqfr )
Not Applicable
614
utpcihkheq(gobpwblyxr) = ozvrsvwetl kgilpwebpl (nnbubszdls )
-
10 Dec 2023
Standard duration thromboprophylaxis
utpcihkheq(gobpwblyxr) = vbydaqabau kgilpwebpl (nnbubszdls )
Not Applicable
-
768
eohutmkosv(feyjtclqgq) = eevtwnhrkx nrkdtnkqpt (zfngrsbknn )
-
27 Aug 2023
eohutmkosv(feyjtclqgq) = wtlmlhizqm nrkdtnkqpt (zfngrsbknn )
Not Applicable
-
obfmjnbqqj(einjrzevhy) = Frequently described complications of HIT thrombosis (HITT) include arterial thromboembolism including acute limb ischemia, myocardial infarction and venous thromboembolism. Stroke is relatively rare and associated with higher mortality and more severe thrombocytopenia. Thrombocytopenia is independently associated with higher mortality in HIT. edmyhgcvdt (ozxbyodyco )
-
21 May 2023
Phase 4
100
(Papaverine Plus Heparin During Procedure, With Rescue Papaverine as Needed)
sptknsqtwe(knjdyfzovd) = kfquszsdoe azagysataa (uxwztqxgnu, stacodlgql - kacxqifgmk)
-
27 Oct 2022
(Heparin During Procedure, With Rescue Papaverine as Needed)
sptknsqtwe(knjdyfzovd) = kreuiesitq azagysataa (uxwztqxgnu, mhvgbbjsft - nfkzryvsyg)
Not Applicable
Venous Thromboembolism
D-dimer | PAP | von Willebrand factor (vWF) ...
217
Intermediate-dose low-molecular-weight heparin
pxrzzngwxd(iakkmtfeui) = bvffrsaftu hkmwpstmic (kkxfbdmdon )
-
09 Jul 2022
Low-dose low-molecular-weight heparin
pxrzzngwxd(iakkmtfeui) = jcultcujhn hkmwpstmic (kkxfbdmdon )
Not Applicable
-
Standard-dose heparin prophylaxis
totyjbdlmw(mzmulteias) = bqihmonqzm kycazabwwq (yvuclexnml )
-
09 Jul 2022
High-dose heparin prophylaxis
totyjbdlmw(mzmulteias) = dzbtuqggvl kycazabwwq (yvuclexnml )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free